Solana Co — fact timeline

Solana Co entered into Amended and Restated Sales Agreement with Clear Street LLC and Maxim Group LLC valued at increase the aggregate gross sales price of Shares that may be offered and sold from time to time fr (effective 2026-05-29).

“On May 29, 2026, Solana Company (the “Company”) entered into an Amended and Restated Sales Agreement (the “Sales Agreement”) with Clear Street LLC (“Clear Street”) and Maxim Group LLC (“Maxim”) (each, an “Agent,” and, together, the “Agents”), as co-sales agents, pursuant to which the Company may offer and sell shares of the Company’s Class A common stock, par value $0.001 per share (the “Shares”) from time to time in connection with its existing “at-the-market” offering of Shares (the “Offering”).”

Solana Co shareholders approved Election of two additional directors to serve until 2027 annual meeting at the 2026-05-21 meeting.

“Proposal 3 : Election of two additional directors, each to serve for a one-year term until the 2027 annual meeting of stockholders or until his successor is duly elected and qualified or until his earlier death, resignation or removal. ​ Nominee Votes For Votes Withheld Broker Non-Votes Michel Lee 13,483,333 307,273 15,063,041 Sergio Mello 13,535,705 254,901 15,063,041”

Solana Co shareholders approved Ratification of appointment of CBIZ CPAs P.C. as independent registered public accounting firm for fiscal year ending December 31, 2026 at the 2026-05-21 meeting.

“Proposal 2: Ratification of the appointment of CBIZ CPAs P.C. as the Company’s independent registered public accounting firm for the year ending December 31, 2026: ​ ​ Votes For Votes Against Abstain Broker Non-Votes 28,738,836 47,612 67,199 15,063,041”

Solana Co shareholders approved Election of four directors to serve until 2027 annual meeting at the 2026-05-21 meeting.

“Proposal 1 : Election of four directors, each to serve for a one-year term until the 2027 annual meeting of stockholders or until his successor is duly elected and qualified or until his earlier death, resignation or removal. ​ Nominee Votes For Votes Withheld Broker Non-Votes Joseph Chee 13,416,280 374,326 15,063,041 Blane Walter 13,518,395 272,211 15,063,041 Edward M. Straw 13,523,716 266,890 15,063,041 Cosmo Jiang 13,334,028 456,578 15,063,041”

Solana Co reported the quarter ended March 31, 2026 results: revenue $3.6 million, net income $99.8 million, or a loss of $1.30 per basic and diluted common share.

“HSDT) (the “Company” or “HSDT”), a publicly listed company, today announced results for the quarter ended March 31, 2026. First Quarter Recent Business Updates ● Generated $3.6 million in revenue in the first quarter of 2026, with the increase primarily driven by the Company’s SOL earning staking yield ● Executed approximately $3.5 million in share repurchases”

Solana Co issued 3,076,922 shares of Class A common stock of common stock to global institutional investor Mirae Asset and Hashkey Capital for $2.60 per share.

“Solana Company (NASDAQ: HSDT) (“HSDT” or the “Company”), a publicly listed company that has expanded its business to include a digital asset treasury dedicated to acquiring and holding Solana tokens (“SOL”), today announced that it has entered into a definitive agreement providing for the purchase and sale of an aggregate of 3,076,922 shares of Class A common stock at a purchase price of $2.60 per share.”

Solana Co reported financial results for the fiscal quarter and year ended December 31, 2025.

“On March 30, 2026, Solana Company (formerly known as Helius Medical Technologies, Inc.) (the “Company”) issued a press release announcing financial results for the fiscal quarter and year ended December 31, 2025. A copy of the press release is being furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.”

Solana Co engaged CBIZ CPAs P.C. as its auditor.

“On October 15, 2025, the Committee approved the appointment of CBIZ CPAs P.C. (“CBIZ CPAs”) as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2025.”

Baker Tilly US, LLP resigned as auditor of Solana Co.

“On October 15, 2025, the Audit Committee (the “Committee”) of the Board of Directors of Solana Corporation (formerly known as Helius Medical Technologies, Inc.) (the “Company”) received the resignation of Baker Tilly US, LLP (“Baker Tilly”) as the Company’s independent registered public accounting firm, effective immediately.”

Solana Co: Second Amended and Restated Bylaws amended solely to reflect the name change to Solana Company (effective 2025-09-29).

“Additionally, the Board approved an amendment to the Company’s Second Amended and Restated Bylaws solely to reflect the Name Change (the “Third Amended and Restated Bylaws”). The Third Amended and Restated Bylaws will become effective immediately after the Name Change on September 29, 2025.”

Solana Co: Company name changed from Helius Medical Technologies, Inc. to Solana Company via Certificate of Amendment (effective 2025-09-29).

“On September 25, 2025, the Board of Directors (the “Board”) of Helius Medical Technologies, Inc. (the “Company”) approved an amendment to the Company’s Certificate of Incorporation, as filed with the Secretary of State of the State of Delaware on July 18, 2018 (the “Certificate of Incorporation”), to change the Company’s name to Solana Company (the “Name Change”). On September 26, 2025, the Company filed with the Secretary of State of the State of Delaware a Certificate of Amendment (the “Certificate of Amendment”) to the Certificate of Incorporation, which will effect the Name Change at 8:00 a.m. Eastern Time on September 29, 2025.”

Solana Co issued stapled warrants to purchase 10,994,199 shares of Common Stock of warrant to accredited investors for $10.134 per underlying Share.

“(ii) stapled warrants (the “Cryptocurrency Stapled Warrants” and together with the Cryptocurrency Pre-Funded Warrants, the “Cryptocurrency Warrants”) to purchase 10,994,199 shares of Common Stock at an exercise price of $10.134 per underlying Share of Common”

Solana Co issued pre-funded warrants to purchase 10,994,199 shares of Common Stock of warrant to accredited investors for $6.880.

“(i) pre-funded warrants (the “Cryptocurrency Pre-Funded Warrants”) to purchase 10,994,199 shares of Common Stock at an offering price of $6.880”

Solana Co issued stapled warrants to purchase 62,946,990 shares of Common Stock of warrant to accredited investors for $10.134 per underlying share.

“(iii) stapled warrants (the “Cash Stapled Warrants”) to purchase 62,946,990 shares of Common Stock at an exercise price of $10.134 per underlying share of Common Stock”

Solana Co issued pre-funded warrants to purchase 25,121,713 shares of Common Stock of warrant to accredited investors for $6.880 per underlying share.

“(ii) pre-funded warrants (the “Cash Pre-Funded Warrants”) to purchase 25,121,713 shares of Common Stock at an offering price of $6.880 per underlying share of Common Stock”

Solana Co issued 37,825,277 shares of common stock to accredited investors for $6.881 per share.

“the Company, in a private placement (the “Cash Offering”), agreed to issue and sell to the Cash Purchasers an aggregate of (i) 37,825,277 shares of Class A common stock of the Company, par value $0.001 per share (the “Common Stock”) at an offering price of $6.881 per share”

Solana Co: Increased authorized common stock to 800,000,000 shares via Certificate of Amendment (effective 2025-09-15).

“On September 15, 2025, the Company filed with the Secretary of State of the State of Delaware a Certificate of Amendment to its Certificate of Incorporation (the “Certificate of Amendment”) to effect the Share Increase, which became effective as of September 15, 2025.”

Solana Co issued pre-funded warrants to purchase shares of Common Stock of warrant to accredited investors for $6.881 less $0.001.

“pre-funded warrants (the “ Cash Pre-Funded Warrants ”) to purchase shares of the Common Stock (the “ Cash Pre-Funded Warrant Shares ”) at an offering price of the Per Share Cash Purchase Price less $0.001 per Cash Pre-Funded Warrant”

Solana Co issued shares of Class A common stock of common stock to accredited investors for $6.881 per Cash Share.

“the Company agreed to sell and issue to the Cash Purchasers in a private placement offering (the “ Cash Offering ”) an aggregate offering of (i) either shares (the “ Cash Shares ”) of Class A common stock of the Company, par value $0.001 per share (the “ Common Stock ”) at an offering price of $6.881 per Cash Share”

Solana Co: Amended Certificate of Incorporation to effect a 1-for-15 reverse stock split (effective 2025-05-02).

“On April 30, 2025, the Company filed with the Secretary of State of the State of Delaware a Certificate of Amendment to its Certificate of Incorporation (the “ Certificate of Amendment ”) to effect the Reverse Stock Split.”

Solana Co incurred loan of $1,560,000 at 20.0% per annum maturing July 24, 2025.

“On April 24, 2025, Helius Medical Technologies, Inc., a Delaware corporation (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with certain investors (the “Purchasers”) pursuant to which the Company sold, in a private placement (the “Offering”), unsecured 20% original issue discount promissory notes with an aggregate principal amount of $1,560,000 (the “Notes”).”

Solana Co received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).

“March 31, 2025, Helius Medical Technologies, Inc. (the “Company”) received written notice (the “Notice”) from the Nasdaq Stock Market LLC (“Nasdaq”) stating that the Company no longer complies with the minimum stockholders’ equity requirement under Nasdaq Listing Rule 5550(b)(1) (the “Stockholders’ Equity Requirement”) for continued listing on The Nasdaq Stock Market LLC because the Company’s stockholders’ equity, as reported in the Company’s Annual Report on Form 10-K for the fourth quarter and year ended December 31, 2024, has fallen below $2.5 million. The notice also indicates that the Com”

Solana Co received a nasdaq delisting notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

“February 7, 2025, the Company received a letter from the Staff indicating the Company’s continued non-compliance with the Minimum Bid Price Requirement. The letter further informed the Company that the Company’s common stock would be delisted from The Nasdaq Capital Market unless the Company appeals the Staff’s delisting determination by requesting a hearing before the Nasdaq Hearings Panel (the “Panel”). The Company’s request for a hearing will stay any further delisting action by the Staff pending the ultimate outcome of the hearing. The Company’s common stock will remain listed and eligible”

Solana Co received a nasdaq delisting notice notice regarding minimum bid price (rules 5550(a)(2)).

“February 7, 2025, the Company received a letter from the Staff indicating the Company’s continued non-compliance with the Minimum Bid Price Requirement. The letter further informed the Company that the Company’s common s”

Solana Co reported quarter ended March 31, 2024 results: revenue $135 thousand, net income net loss of $2.5 million, EPS $3.08 per share.

“Services to make PoNS available to federal healthcare systems, including the U.S. Department of Veterans Affairs (“VA”) and Department of Defense (“DoD”). ​ ● Q1 2024 revenue of $135 thousand, compared to $111 thousand in Q1 2023, reflecting increased product sales in both the U.S. and Canada . ​ ● Closed on $6.4 million public offering, raising net proceeds of”

Solana Co entered into Placement Agency Agreement with Craig-Hallum Capital Group LLC valued at approximately $6.4 million (effective 2024-05-06).

“On May 6, 2024, Helius Medical Technologies, Inc., (the “Company”), entered into a placement agency agreement (the “Placement Agency Agreement”) with Craig-Hallum Capital Group LLC (the “Placement Agent”) for the purchase and sale, in a registered public offering by the Company (the “Public Offering”) of 704,999 shares of its Class A common stock, par value $0.001 per share (“Common Stock”) and 2,147,222 pre-funded warrants, each to purchase one share of Common Stock at an exercise price of $0.001 per share (the “Pre-funded Warrants”) together with accompanying Series A Warrants to purchase up to 2,852,221 shares of its Common Stock (“Series A Warrants”) and Series B Warrants to purchase up to 2,852,221 shares of its Common Stock (“Series B Warrants”, and together with the Series A Warrants, the “Public Warrants”).”

Solana Co received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).

“April 4, 2024, Helius Medical Technologies, Inc. (the “Company”) received written notice from the Nasdaq Stock Market LLC (“Nasdaq”) stating that the Company no longer complies with the minimum stockholders’ equity requirement under Nasdaq Listing Rule 5550(b)(1) for continued listing on The Nasdaq Stock Market LLC because the Company’s stockholders' equity, as reported in the Company’s Annual Report on Form 10-K for the fourth quarter and year ended December 31, 2023, has fallen below $2.5 million. The notice also indicates that the Company does not meet the alternative compliance standards.”

Solana Co reported financial results for the quarter and full year ended December 31, 2023.

“On March 28, 2024, Helius Medical Technologies, Inc. (the “Registrant”) issued a press release announcing its financial results for the quarter and year ended December 31, 2023, as well as information regarding a conference call to discuss these financial results and the Registrant’s recent corporate highlights.”

Solana Co: Amended and restated bylaws to reduce stockholder meeting quorum, address universal proxy rules, update disclosure requirements, impose new special meeting nomination conditions, and clarify personal jurisdiction (effective 2024-03-12).

“On March 12, 2024, the Board of Directors (the “ Board ”) of Helius Medical Technologies, Inc., a Delaware corporation (the “ Company ”) approved and adopted the Company’s Second Amended and Restated Bylaws (the “ Second Amended and Restated Bylaws ”), which became effective the same day.”

Solana Co reported the quarter ended September 30, 2023 results: revenue $143 thousand, net income Net loss was $3.7 million for the third quarter of 2023.

“approach for balance and gait deficits, today announced results for the quarter ended September 30, 2023. Third Quarter and Recent Business Updates ● Q3 2023 revenue of $143 thousand, compared to $196 thousand in Q3 2022, the decrease due to the expiration of the Patient Therapy Access Program (“PTAP”) on June 30, 2023. ● Operating cash burn of $2.5 million”

Solana Co reported the quarter ended September 30, 2023 results: revenue $140 - $150 thousand. Guidance initiated.

“Expects to report Q3 revenues in range of $140 - $150 thousand, reflecting the expected decrease in U.S. sales with the conclusion of the Patient Therapy Access Program (PTAP) on June 30, 2023”

Solana Co reported the quarter ended June 30, 2023 results: revenue $256 thousand, net income $1.6 million, EPS $0.06 per share. Guidance initiated.

“Total revenue for the second quarter of 2023 was $256 thousand, an increase of $137 thousand compared to $119 thousand in the second quarter of 2022”

Solana Co entered into Sales Agreement with Roth Capital Partners, LLC valued at up to $1.95 million (effective 2023-06-23).

“On June 23, 2023, Helius Medical Technologies, Inc. (the “Company”) entered into a Sales Agreement (the “Sales Agreement”) with Roth Capital Partners, LLC, as agent (the “Sales Agent”). Pursuant to the Sales Agreement, the Company may offer and sell up to $1.95 million in shares of Class A common stock, par value $0.001 per share (the “Shares”), from time to time through the Sales Agent.”

Solana Co shareholders approved Approval to authorize one or more adjournments of the Annual Meeting to solicit additional proxies in the event there are insufficient votes to approve Proposal 3 at the 2023-05-24 meeting.

“Proposal 4 — Approval to authorize one or more adjournments of the Annual Meeting to solicit additional proxies in the event there are insufficient votes to approve Proposal 3 described above: ​ Votes For Votes Against Abstain 9,595,316,731 ​ 2,478,745,269 ​ 83,625,542”

Solana Co shareholders approved Approval of an amendment to the Company's Certificate of Incorporation to effect a reverse split of its outstanding Class A common stock at a ratio in the range of 1-for-10 to 1-for-80 to be determined at the discretion of the Company's Board of Directors, whereby each outstanding 10 to 80 shares wo at the 2023-05-24 meeting.

“Proposal 3 —Approval of an amendment to the Company’s Certificate of Incorporation to effect a reverse split of its outstanding Class A common stock at a ratio in the range of 1-for-10 to 1-for-80 to be determined at the discretion of the Company’s Board of Directors, whereby each outstanding 10 to 80 shares would be combined, converted and changed into 1 share of the Company’s Class A common stock, to enable the Company to comply with the Nasdaq Stock Market’s continued listing requirements: ​ Votes For Votes Against Abstain 9,092,567,484 ​ 3,050,157,110 ​ 14,962,948”

Solana Co shareholders approved Ratification of the appointment of Baker Tilly US, LLP as the Company's independent registered public accounting firm for the year ending December 31, 2023 at the 2023-05-24 meeting.

“Proposal 2 —Ratification of the appointment of Baker Tilly US, LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2023: ​ Votes For Votes Against Abstain 10,999,837 ​ 1,122,654 ​ 23,051”

Solana Co shareholders approved Election of six directors named in the accompanying proxy statement, each to serve for a one-year term until the 2024 annual meeting of stockholders or until his or her successor is duly elected and qualified or until his or her earlier death, resignation or removal. at the 2023-05-24 meeting.

“Nominee Votes For Votes Withheld Broker Non-Votes Blane Walter 4,766,800 ​ 1,094,105 ​ 6,284,637 Dane C. Andreeff ​ 4,739,896 ​ 1,121,009 ​ 6,284,637 Edward M. Straw ​ 4,717,566 ​ 1,143,339 ​ 6,284,637 Jeffrey Mathiesen ​ 4,784,422 ​ 1,076,483 ​ 6,284,637 Paul Buckman ​ 4,784,444 ​ 1,076,461 ​ 6,284,637 Sherrie Perkins ​ 4,795,767 ​ 1,065,138 ​ 6,284,637”

Solana Co reported the quarter ended March 31, 2023 results: revenue $111 thousand, net income $2.5 million, EPS $0.09 per share. Guidance initiated.

“Total revenue for the first quarter of 2023 was $111 thousand, a decrease of $79 thousand compared to $190 thousand in the first quarter of 2022, primarily attributable to lower Canada product sales, partially offset by increased net product sales in the United States. Commercial product sales in the United States commenced in April 2022. Canada product sales for the three months ended March 31, 2022 included approximately $120 thousand of revenue recognized in connection with the delivery of PoNS devices under our prior distribution agreement with HTC. Cost of revenue was $122 thousand for the three months ended March 31, 2023, compared to $124 thousand for the comparable period in 2022, remaining relatively flat due to fixed overhead costs. Operating expenses for the first quarter of 2023 decreased to $3.8 million, compared to $4.6 million in the first quarter of 2022. The decrease was driven primarily by a decrease in product development expenses and clinical trial activities as we”

Solana Co: Filed Certificate of Designation for Series B Preferred Stock, amending the certificate of incorporation (effective 2023-03-24).

“The Certificate of Designation was filed with the Delaware Secretary of State and became effective on March 24, 2023. The foregoing description of the Series B Preferred Stock does not purport to be complete and is qualified in its entirety by reference to the Certificate of Designation, which is filed as Exhibit 3.1(a) to this Current Report and is incorporated herein by reference.”

Solana Co received a nasdaq extension granted notice regarding minimum bid price (rules 5550(a)(2)).

“March 21, 2023, Helius Medical Technologies, Inc. (the “ Company ”) received a letter (the “ Extension Notice ”) from the Listing Qualifications Staff of The Nasdaq Stock Market, LLC (“ Nasdaq ”) notifying the Company that Nasdaq has granted the Company a 180-day extension, until September 18, 2023 (the “Extension Period”), to regain compliance with the requirement for the Company’s common stock, par value $0.001 per share (“ Common Stock ”), to maintain a minimum bid price of $1.00 per share for continued listing on the Nasdaq Capital Market, as set forth in Nasdaq Listing Rule 5550(a)(2) (th”

Solana Co updated its 2023 guidance (initiated).

“2023 Guidance The Company currently expects 2023 revenues to exceed prior year levels and increase throughout the year, though we may experience quarterly fluctuations as we make refinements to our U.S. commercial roll-out of PoNS.”

Solana Co reported Full Year 2022 results: revenue $787 thousand, net income $14.1 million, EPS $1.04.

“Total revenue for the full year 2022 was $787 thousand, compared to $522 thousand for the full year 2021, reflecting the U.S. commercial launch of PoNS for MS in April 2022, partially offset by a decrease in product sales in Canada, mostly attributable to lower Canadian to U.S. dollar translation rates during 2022. Cost of revenue for the full year 2022 increased $165 thousand to $463 thousand, compared to cost of revenue of $298 thousand for the full year 2021, primarily attributable to overhead costs, including salaries and benefits of employees involved in management of the supply chain, and inventory-related cost of sales due to higher sales volume. Gross profit for the full year 2022 was $324 thousand, compared to gross profit of $224 thousand for the full year 2021. Operating expenses for the full year 2022 decreased $2.5 million to $15.8 million, compared to $18.4 million for the full year 2021, due primarily to a $2.0 million decrease in stock-based compensation expense and a d”

Solana Co reported Q4 2022 results: revenue $282 thousand, net income $4.9 million, EPS $0.17.

“Total revenue for the fourth quarter of 2022 was $282 thousand, an increase of 9% compared to $258 thousand in the fourth quarter of 2021 and was comprised primarily of product sales in both periods. Cost of revenues was $150 thousand for the three months ended December 31, 2022, compared to $129 thousand for the comparable period in 2021, primarily due to increased revenues. Gross profit for the fourth quarter of 2022 was $132 thousand, compared to gross profit of $129 thousand in the fourth quarter of 2021. Operating expenses for the fourth quarter of 2022 decreased to $2.8 million, compared to $4.2 million in the fourth quarter of 2021. The decrease was primarily the result of lower product development and clinical trial activities following the U.S. commercial launch of PoNS. Operating loss for the fourth quarter of 2022 decreased $1.4 million to a loss of $2.7 million, compared to an operating loss of $4.1 million in the fourth quarter of 2021. Net loss was $4.9 million for the fo”

Solana Co reported full year ended December 31, 2022 results: revenue $780,000 to $790,000.

“Full year 2022 revenue projected to range from $780,000 to $790,000”

Solana Co reported quarter ended December 31, 2022 results: revenue $275,000 to $285,000.

“Q4 2022 revenue projected to range from $275,000 to $285,000”

Mitchell Tyler departed as Director at Solana Co.

“Mr. Mitchell Tyler notified the Board of Directors (the “Board”) of Helius Medical Technologies, Inc. (the “Company”) of his intention to retire from service on the Board upon expiration of his current term”

Paul Buckman was appointed as Director at Solana Co.

“approved an increase in the size of the Board from five to six directors and the appointment of Paul Buckman to fill the vacancy created by such increase, which appointment became effective on September 10, 2021 upon Mr. Buckman’s acceptance.”

Joyce LaViscount resigned as Chief Operating Officer at Solana Co.

“the employment of Joyce LaViscount, Chief Operating Officer of Helius Medical Technologies, Inc. (the “Company”) ended on July 20, 2021”

Joyce LaViscount departed as Chief Operating Officer at Solana Co.

“The employment of Joyce LaViscount, Chief Operating Officer of Helius Medical Technologies, Inc. ended on July 20, 2021.”